An interventional study of tDCS intervention applied by Starstim device in Major Depressive Disorder, sponsored by Neuroelectrics Corporation. Status unknown at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-05.
Sponsored by Neuroelectrics Corporation · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 216 open to participants now, 258 under way, 26 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 912th largest by enrollment of the 1,323 interventional ones that give a count, is one of 52 that started in 2022, is one of 472 with no phase, and was the 1,160th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →216 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
University of Kentucky · Sites in United States
Ages 18–75
Eli Lilly and Company · Sites in United States, Bulgaria, Hungary and 5 more countries
Ages 18–75
Alkermes, Inc. · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 52 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 585 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
Neuroelectrics Corporation is the lead sponsor of 3 studies on the registry; none are open to participants now.
Neuroelectrics Corporation has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
98 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 98 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open label pilot feasibility telemedicine study. This pilot will involve a total of 37 at-home stimulation sessions (30-minutes each) of multichannel excitatory tDCS targeting the left dorsolateral prefrontal cortex (DLPFC) administered over 8 weeks, with a follow-up period of 4 weeks following the final stimulation session.
This is an open label pilot feasibility telemedicine study. This pilot will involve a total of 37 at-home stimulation sessions (30-minutes each) of multichannel excitatory tDCS targeting the left dorsolateral prefrontal cortex (DLPFC) administered over 8 weeks, with a follow-up period of 4 weeks following the final stimulation session.
The main objective of the study is to assess the feasibility and safety of home-based tDCS for patients with MDD.
The treatment course will consist of an acute phase of 28 tDCS sessions, conducted daily (7 days per week) over 4 weeks.
Thereafter, participants will undergo a taper phase of an additional 9 sessions of tDCS applied in progressively decreasing frequency until day #60 of the study as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients will receive active treatment which consists of stimulation (tDCS) applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents).
Device: tDCS intervention applied by Starstim device
Stimulation will be applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents). The montage has been designed to optimize anodal stimulation in the desired target area while avoiding stimulation off target.
Also known as: Starstim
Percentage of incomplete and missed sessions (%)
Feasibility will be evaluated using home-based data as recorded in the Neuroelectrics portal. Range \[0,100\]. Higher is worse
Time frame: From baseline to 4-week follow up across study subjects
Incidence of Serious Adverse Events (SAE)
Safety will be assessed by number and type of side effects
Time frame: From baseline to 4-week follow up across study subjects
Median percentage change in Montgomery-Asberg Depression Mood Rating Scale (MADRS) scores
The primary efficacy measure for this study will be the median percent change from baseline to the end of the 4-week post-treatment follow-up period in the observer-rated Montgomery-Asberg Depression Mood Rating Scale (MADRS) (Montgomery and Asberg, 1979). Range \[0,100\]. Higher is worse
Time frame: From baseline to 4-week follow up across study subjects
Response rate
Response rate is the secondary efficacy endpoint and will be calculated for the study subjects, where clinical response is defined as ≥ 50% improvement in Montgomery-Asberg Depression Mood Rating Scale (MADRS) score. Higher is better
Time frame: From baseline to the 4-week follow-up
Change in the Quick Inventory of Depressive Symptomatology (QIDS-SR) score
Range \[0,27\]. Higher is worse
Time frame: Change from baseline to 4-week follow-up in the participant-rated Quick Inventory of Depressive Symptomatology (QIDS-SR)
Change in the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) score
Range \[14,70\]. Higher is better
Time frame: Change from baseline to 4-week follow-up in the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF)
Median percentage change in Montgomery-Asberg Depression Mood Rating Scale (MADRS) scores
Time frame: From baseline to the end of week 4 of treatment, and to the end of week 8 of treatment.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2022 (actual). Primary completion is estimated for Dec 2022, 10 months after the start.
Of 40 industry-sponsored interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's planned 10 months is below that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.